{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:12:17Z","timestamp":1788667937890,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Intergroup Francophone du My\u00e9lome"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00992-2","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:17:59Z","timestamp":1788617879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma"],"prefix":"10.1186","volume":"14","author":[{"given":"Wenwen","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gaggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Hasan Bou Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00efcha","family":"Ouelkdite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Escure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanick","family":"Njosse Tchantchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Wauquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthier","family":"Decool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Tilmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Podvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malo","family":"Leprohon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Shekarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lina","family":"Kasprowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Groux-Degroote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Villenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Martinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Figeac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"issue":"14","key":"992_CR1","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1607751.","journal-title":"N Engl J Med"},{"issue":"22","key":"992_CR2","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1817249.","journal-title":"N Engl J Med"},{"issue":"3","key":"992_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2022017635","volume":"143","author":"T Facon","year":"2024","unstructured":"Facon T, Leleu X, Manier S. How I treat multiple myeloma in geriatric patients. Blood. 2024;143(3):224\u201332. https:\/\/doi.org\/10.1182\/blood.2022017635.","journal-title":"Blood"},{"issue":"1","key":"992_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","volume":"9","author":"L Sanchez","year":"2016","unstructured":"Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):51. https:\/\/doi.org\/10.1186\/s13045-016-0283-0.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"992_CR5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41467-024-45561-z","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu J, Xing L, Li J, Wen K, Liu N, Liu Y, et al. Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma. Nat Commun. 2024;15(1):1367. https:\/\/doi.org\/10.1038\/s41467-024-45561-z.","journal-title":"Nat Commun"},{"issue":"3","key":"992_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38\u2009+\u2009immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749.","journal-title":"Blood"},{"issue":"21","key":"992_CR7","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","volume":"126","author":"EC Fink","year":"2015","unstructured":"Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126(21):2366\u20139. https:\/\/doi.org\/10.1182\/blood-2015-07-567958.","journal-title":"Blood"},{"issue":"6168","key":"992_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301\u20135. https:\/\/doi.org\/10.1126\/science.1244851.","journal-title":"Science"},{"issue":"2","key":"992_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","volume":"35","author":"T Casneuf","year":"2021","unstructured":"Casneuf T, Adams HC 3rd, van de Donk N, Abraham Y, Bald J, Vanhoof G, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2021;35(2):573\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0855-4.","journal-title":"Leukemia"},{"issue":"22","key":"992_CR10","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","volume":"6","author":"C Schinke","year":"2022","unstructured":"Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022;6(22):5873\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2022007217.","journal-title":"Blood Adv"},{"issue":"1","key":"992_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, et al. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024;14(1):194. https:\/\/doi.org\/10.1038\/s41408-024-01172-x.","journal-title":"Blood Cancer J"},{"issue":"5","key":"992_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1(5):493\u2013506. https:\/\/doi.org\/10.1038\/s43018-020-0053-3.","journal-title":"Nat Cancer"},{"issue":"12","key":"992_CR13","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1182\/blood.2023023529","volume":"144","author":"E Blanquart","year":"2024","unstructured":"Blanquart E, Ekren R, Rigaud B, Joubert MV, Baylot V, Daunes H, et al. NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma. Blood. 2024;144(12):1271\u201383. https:\/\/doi.org\/10.1182\/blood.2023023529.","journal-title":"Blood"},{"issue":"6","key":"992_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","volume":"22","author":"MME de Jong","year":"2021","unstructured":"de Jong MME, Kellermayer Z, Papazian N, Tahri S, Hofste Op Bruinink D, Hoogenboezem R, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol. 2021;22(6):769\u201380. https:\/\/doi.org\/10.1038\/s41590-021-00931-3.","journal-title":"Nat Immunol"},{"key":"992_CR15","doi-asserted-by":"publisher","unstructured":"Oetjen KA, Lindblad KE, Goswami M, Gui G, Dagur PK, Lai C, et al. Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. JCI Insight. 2018;3(23). https:\/\/doi.org\/10.1172\/jci.insight.124928.","DOI":"10.1172\/jci.insight.124928"},{"issue":"1","key":"992_CR16","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier SM, Mallm JP, Steiger S, Poos AM, Awwad MHS, Giesen N, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12(1):6960. https:\/\/doi.org\/10.1038\/s41467-021-26951-z.","journal-title":"Nat Commun"},{"issue":"21","key":"992_CR17","doi-asserted-by":"publisher","first-page":"13353","DOI":"10.1074\/jbc.273.21.13353","volume":"273","author":"H Akiba","year":"1998","unstructured":"Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, Atsuta M, et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase\/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem. 1998;273(21):13353\u20138. https:\/\/doi.org\/10.1074\/jbc.273.21.13353.","journal-title":"J Biol Chem"},{"issue":"46","key":"992_CR18","doi-asserted-by":"publisher","first-page":"38247","DOI":"10.1074\/jbc.M509378200","volume":"280","author":"MW Feinberg","year":"2005","unstructured":"Feinberg MW, Cao Z, Wara AK, Lebedeva MA, Senbanerjee S, Jain MK. Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J Biol Chem. 2005;280(46):38247\u201358. https:\/\/doi.org\/10.1074\/jbc.M509378200.","journal-title":"J Biol Chem"},{"issue":"9","key":"992_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv LB. IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545\u201358. https:\/\/doi.org\/10.1038\/s41577-018-0029-z.","journal-title":"Nat Rev Immunol"},{"key":"992_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","volume":"34","author":"D Vrabel","year":"2019","unstructured":"Vrabel D, Pour L, Sevcikova S. The impact of NF-kappaB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2019;34:56\u201366. https:\/\/doi.org\/10.1016\/j.blre.2018.11.003.","journal-title":"Blood Rev"},{"issue":"6","key":"992_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883\u201399. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025.","journal-title":"Cell"},{"issue":"23","key":"992_CR22","doi-asserted-by":"publisher","first-page":"11432","DOI":"10.1158\/0008-5472.CAN-06-1867","volume":"66","author":"A Saccani","year":"2006","unstructured":"Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006;66(23):11432\u201340. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1867.","journal-title":"Cancer Res"},{"issue":"3","key":"992_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2004.08.012","volume":"6","author":"JL Luo","year":"2004","unstructured":"Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 2004;6(3):297\u2013305. https:\/\/doi.org\/10.1016\/j.ccr.2004.08.012.","journal-title":"Cancer Cell"},{"issue":"6","key":"992_CR24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20080108","volume":"205","author":"T Hagemann","year":"2008","unstructured":"Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, et al. Re-educating tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205(6):1261\u20138. https:\/\/doi.org\/10.1084\/jem.20080108.","journal-title":"J Exp Med"},{"issue":"5234","key":"992_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.270.5234.286","volume":"270","author":"N Auphan","year":"1995","unstructured":"Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286\u201390. https:\/\/doi.org\/10.1126\/science.270.5234.286.","journal-title":"Science"},{"issue":"10","key":"992_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","volume":"29","author":"N Jacquelot","year":"2019","unstructured":"Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, et al. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019;29(10):846\u201361. https:\/\/doi.org\/10.1038\/s41422-019-0224-x.","journal-title":"Cell Res"},{"issue":"6702","key":"992_CR27","doi-asserted-by":"publisher","first-page":"eade8520","DOI":"10.1126\/science.ade8520","volume":"384","author":"J Zak","year":"2024","unstructured":"Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 2024;384(6702):eade8520. https:\/\/doi.org\/10.1126\/science.ade8520.","journal-title":"Science"},{"issue":"6702","key":"992_CR28","doi-asserted-by":"publisher","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science. 2024;384(6702):eadf1329. https:\/\/doi.org\/10.1126\/science.adf1329.","journal-title":"Science"},{"issue":"1","key":"992_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s43018-022-00490-y","volume":"4","author":"J Qiu","year":"2023","unstructured":"Qiu J, Xu B, Ye D, Ren D, Wang S, Benci JL, et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat Cancer. 2023;4(1):43\u201361. https:\/\/doi.org\/10.1038\/s43018-022-00490-y.","journal-title":"Nat Cancer"},{"issue":"2","key":"992_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaci.2016.10.051","volume":"140","author":"G Tabellini","year":"2017","unstructured":"Tabellini G, Vairo D, Scomodon O, Tamassia N, Ferraro RM, Patrizi O, et al. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2017;140(2):553\u2013e644. https:\/\/doi.org\/10.1016\/j.jaci.2016.10.051.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"992_CR31","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1002\/cpz1.589","volume":"2","author":"CE Whyte","year":"2022","unstructured":"Whyte CE, Tumes DJ, Liston A, Burton OT. Do more with Less: Improving High Parameter Cytometry Through Overnight Staining. Curr Protoc. 2022;2(11):e589. https:\/\/doi.org\/10.1002\/cpz1.589.","journal-title":"Curr Protoc"},{"issue":"7787","key":"992_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41586-019-1825-8","volume":"576","author":"R Argelaguet","year":"2019","unstructured":"Argelaguet R, Clark SJ, Mohammed H, Stapel LC, Krueger C, Kapourani CA, et al. Multi-omics profiling of mouse gastrulation at single-cell resolution. Nature. 2019;576(7787):487\u201391. https:\/\/doi.org\/10.1038\/s41586-019-1825-8.","journal-title":"Nature"},{"issue":"12","key":"992_CR33","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739\u201340. https:\/\/doi.org\/10.1093\/bioinformatics\/btr260.","journal-title":"Bioinformatics"},{"issue":"12","key":"992_CR34","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41587-020-0591-3","volume":"38","author":"V Bergen","year":"2020","unstructured":"Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat Biotechnol. 2020;38(12):1408\u201314. https:\/\/doi.org\/10.1038\/s41587-020-0591-3.","journal-title":"Nat Biotechnol"},{"issue":"6282","key":"992_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189\u201396. https:\/\/doi.org\/10.1126\/science.aad0501.","journal-title":"Science"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00992-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:49:27Z","timestamp":1788666567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00992-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00992-2","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The French National Agency for the Safety of Medicines and Health (ANSM) and the Ethical Committee \u201cSud-Mediterranee II\u201d (reference 219 A10) approved the protocol (ID# 19.02.28.43641). The IFM2017-03 trial (registered as NCT03993912 on 2019-10-17,\n                      \n                      ) and the correlative studies were conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All the patients provided written informed consent. The trial was promoted by Lille University Hospital (CHU Lille) in collaboration with the IFM and with the support of Johnson and Johnson.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants in this study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"119"}}